Omega-3: safety and interactions

Fish oil tolerability, warfarin and risk signals in studies.

Key points

  • Fish oil supplements can cause unpleasant aftertaste, belching, heartburn, nausea or diarrhea. Consider tolerability of the specific product. [1] See the evidence 1
  • Fish oil may change INR when taken with warfarin. When starting, stopping or changing the supplement dose, agree on monitoring with a healthcare professional and do not change the warfarin dose yourself. [1] [2] See the evidence 1
  • In studies of adults at high cardiovascular risk, atrial fibrillation was more frequent at over 1.5 g EPA and DHA daily. If you have an arrhythmia and are choosing high doses, discuss composition with a healthcare professional. [3] [1] See the evidence 1 2

Practical guide

Check the conclusions and whether they apply to your situation.

Risks depend on composition, dose and the person’s condition.

Key points

Why these conclusions

What is known about safety

Fish oil supplements can cause unpleasant aftertaste, belching, heartburn, nausea or diarrhea. [1]

Warfarin and fish oil supplements (marine EPA/DHA): Fish oil may change INR when taken with warfarin. In a small RCT with 16 enrolled participants, five of whom dropped out, no clear INR difference from placebo was detected over four weeks; the result applies to the products and conditions studied. When starting, stopping or changing a fish oil dose, tell the professional monitoring warfarin the product composition and dose and agree on INR monitoring; do not change the warfarin dose yourself. [1] [2]

A review of 35 studies with 114,592 participants separately compared studies of people at high cardiovascular risk receiving over 1.5 g EPA+DHA daily. In this group of studies, atrial fibrillation occurred more often: odds ratio 1.43 (95% CI 1.14–1.79), absolute difference +0.8 percentage points. The review included trials in adults aged 50 and over taking EPA/DHA for at least one year. The dose threshold grouped studies; it does not establish an individual safe dose. [3]

In a review of 11 trials, overall bleeding frequency did not differ convincingly: RR 1.09 (95% CI 0.91–1.31). High-dose purified EPA, a separate prescription intervention, showed an increase: RR 1.50 (95% CI 1.13–1.99), absolute difference about +0.6 percentage points. This subgroup result applies to the studied product and regimen. [4]

In a review, additional long-chain omega-3 during pregnancy was associated with more pregnancies continuing beyond 42 weeks: 2.6% versus 1.6%, RR 1.61 (95% CI 1.11–2.33). This is gestational duration, not supplement duration. Studies used different supplements, dietary interventions and intake periods. [5]

In VITAL-DEP, among 18,353 adults aged 50 and over, 1 g fish oil daily (465 mg EPA and 375 mg DHA) over a median 5.3 years was associated with more new or recurrent cases of depression or significant symptoms: 651 versus 583, HR 1.13 (95% CI 1.01–1.26). [6]

Fish oil supplements can cause unpleasant aftertaste, belching, heartburn, nausea or diarrhea.

Fish oil supplements can cause unpleasant aftertaste, belching, heartburn, nausea or diarrhea. [1]

A review of 35 studies with 114,592 participants separately compared studies of people at high cardiovascular risk receiving over 1.5 g EPA+DHA daily. In this group of studies, atrial fibrillation occurred more often: odds ratio 1.43 (95% CI 1.14–1.79), absolute difference +0.8 percentage points. The review included trials in adults aged 50 and over taking EPA/DHA for at least one year. The dose threshold grouped studies; it does not establish an individual safe dose.

A review of 35 studies with 114,592 participants separately compared studies of people at high cardiovascular risk receiving over 1.5 g EPA+DHA daily. In this group of studies, atrial fibrillation occurred more often: odds ratio 1.43 (95% CI 1.14–1.79), absolute difference +0.8 percentage points. The review included trials in adults aged 50 and over taking EPA/DHA for at least one year. The dose threshold grouped studies; it does not establish an individual safe dose. [3]

In a review of 11 trials, overall bleeding frequency did not differ convincingly: RR 1.09 (95% CI 0.91–1.31). High-dose purified EPA, a separate prescription intervention, showed an increase: RR 1.50 (95% CI 1.13–1.99), absolute difference about +0.6 percentage points. This subgroup result applies to the studied product and regimen.

In a review of 11 trials, overall bleeding frequency did not differ convincingly: RR 1.09 (95% CI 0.91–1.31). High-dose purified EPA, a separate prescription intervention, showed an increase: RR 1.50 (95% CI 1.13–1.99), absolute difference about +0.6 percentage points. This subgroup result applies to the studied product and regimen. [4]

In a review, additional long-chain omega-3 during pregnancy was associated with more pregnancies continuing beyond 42 weeks: 2.6% versus 1.6%, RR 1.61 (95% CI 1.11–2.33). This is gestational duration, not supplement duration. Studies used different supplements, dietary interventions and intake periods.

In a review, additional long-chain omega-3 during pregnancy was associated with more pregnancies continuing beyond 42 weeks: 2.6% versus 1.6%, RR 1.61 (95% CI 1.11–2.33). This is gestational duration, not supplement duration. Studies used different supplements, dietary interventions and intake periods. [5]

Warfarin and fish oil supplements (marine EPA/DHA): Fish oil may change INR when taken with warfarin. In a small RCT with 16 enrolled participants, five of whom dropped out, no clear INR difference from placebo was detected over four weeks; the result applies to the products and conditions studied. When starting, stopping or changing a fish oil dose, tell the professional monitoring warfarin the product composition and dose and agree on INR monitoring; do not change the warfarin dose yourself.

Warfarin and fish oil supplements (marine EPA/DHA): Fish oil may change INR when taken with warfarin. In a small RCT with 16 enrolled participants, five of whom dropped out, no clear INR difference from placebo was detected over four weeks; the result applies to the products and conditions studied. When starting, stopping or changing a fish oil dose, tell the professional monitoring warfarin the product composition and dose and agree on INR monitoring; do not change the warfarin dose yourself. [1] [2]

Fishy taste, belching, nausea and diarrhea are possible. Arrhythmia, anticoagulants and high doses require individual assessment; INR monitoring may be needed with warfarin.

Fishy taste, belching, nausea and diarrhea are possible. Arrhythmia, anticoagulants and high doses require individual assessment; INR monitoring may be needed with warfarin. [1]

In VITAL-DEP, among 18,353 adults aged 50 and over, 1 g fish oil daily (465 mg EPA and 375 mg DHA) over a median 5.3 years was associated with more new or recurrent cases of depression or significant symptoms: 651 versus 583, HR 1.13 (95% CI 1.01–1.26).

ParameterData
ResultIn VITAL-DEP, among 18,353 adults aged 50 and over, 1 g fish oil daily (465 mg EPA and 375 mg DHA) over a median 5.3 years was associated with more new or recurrent cases of depression or significant symptoms: 651 versus 583, HR 1.13 (95% CI 1.01–1.26).
ParticipantsAdults aged 50 and over without active depression or clinically significant symptoms at baseline
FormFish oil with specified EPA and DHA composition
Dose465 mg EPA and 375 mg DHA in 1 g oil daily
Dose basis465 mg EPA and 375 mg DHA in 1 g oil daily
ComparatorPlacebo
DurationMedian 5.3 years
Confidence3/4: No additional substantial risk was established for this contrast.; No grounds for a separate downgrade.; Measurement directly addresses the specified narrow PICO.; The lower HR bound is close to 1 and permits a minimal change.; No specific data for a separate downgrade.
Evidence baseNamed publications: 1
Sources[6]

More details

When to discuss use

Arrhythmia, anticoagulant use and choosing high doses require individual assessment. With warfarin, agree on INR monitoring. [1] [2]

Sources

  1. Omega-3 Fatty Acids - Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
  2. Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy. https://pubmed.ncbi.nlm.nih.gov/10767122/
  3. Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals. https://pmc.ncbi.nlm.nih.gov/articles/PMC13489779/
  4. Bleeding Risk in Patients Receiving Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC11179820/
  5. Omega-3 fatty acid addition during pregnancy. https://doi.org/10.1002/14651858.CD003402.pub3
  6. Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC8693224/

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: OMEGA-3 FATTY ACIDS